Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Added Revision: v3.3.3 at the bottom of the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T12:29:52.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.1 to v3.3.2 in the page footer. This is a minor maintenance update and does not affect study information.
    Difference
    0.0%
    Check dated 2025-12-01T17:26:53.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    A new revision label 'Revision: v3.3.1' was added and the previous 'Revision: v3.2.0' label was removed.
    Difference
    0.0%
    Check dated 2025-11-24T14:36:24.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    A government funding/operating status notice was removed from the page; the study details and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-17T06:54:21.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    There are no significant additions or deletions to core page content; the page appears to retain the same sections such as Study Overview, Eligibility Criteria, Study Plan, and Contacts/Locations, with only minor visual adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:17:56.000Z thumbnail image
  9. Check
    87 days ago
    Change Detected
    Summary
    Update includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.
    Difference
    4%
    Check dated 2025-10-05T10:19:45.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.